253 related articles for article (PubMed ID: 29957591)
1. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma.
Kurosawa M; Sutoh E
J Investig Allergol Clin Immunol; 2019; 29(1):40-45. PubMed ID: 29957591
[TBL] [Abstract][Full Text] [Related]
2. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
[TBL] [Abstract][Full Text] [Related]
3. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
[TBL] [Abstract][Full Text] [Related]
5. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
6. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
9. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
10. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
11. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
[TBL] [Abstract][Full Text] [Related]
12. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
[TBL] [Abstract][Full Text] [Related]
16. Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study.
Kurosawa M; Ogawa E; Sutoh E
Eur Ann Allergy Clin Immunol; 2019 Sep; 51(5):213-221. PubMed ID: 30983308
[No Abstract] [Full Text] [Related]
17. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.
Terashima T; Shinozaki T; Iwami E; Nakajima T; Matsuzaki T
BMC Pulm Med; 2018 Mar; 18(1):53. PubMed ID: 29587693
[TBL] [Abstract][Full Text] [Related]
18. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.
Pelaia C; Crimi C; Pelaia G; Nolasco S; Campisi R; Heffler E; Valenti G; Crimi N
Clin Exp Allergy; 2020 Jul; 50(7):780-788. PubMed ID: 32347992
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
